SecBot SecBot
Biotech Drug Report Generated Nov 6, 2026

miricorilant

CORT·CORCEPT THERAPEUTICS INC
NEUTRAL
Drug Impact Rating4/10
Trial phase
Phase 2
Time to market
At least 3-5 years away, if ever. Miricorilant is in Phase 2 development. A Phase 3 program has not yet been initiated, and no regulatory filings have been submitted. The drug is not the company's lead asset.
Why 4/10
No hard dated binary catalyst (PDUFA, pivotal readout) is scheduled for miricorilant in the next ~12 months. The Phase 2b MONARCH results were just announced on November 3, 2026. The next step is a planned Phase 2 study at higher doses, but no specific date has been given. Miricorilant is not Corcept's lead asset (relacorilant is more advanced with a PDUFA on December 17, 2026). ImpactScore is 4 because the drug is a mid-stage pipeline asset with no imminent binary catalyst.
Actionable Insight NEUTRAL

Miricorilant's Phase 2b MONARCH results were just released (Nov 3, 2026) and are now a known event. The next catalyst is the planned Phase 2 study at higher doses, but no date has been set. For Corcept investors, the more immediate binary catalyst is the relacorilant PDUFA on December 17, 2026. Miricorilant remains an early-stage pipeline asset; positive MONARCH data de-risks the mechanism somewhat, but the drug is years away from any regulatory decision.

Price Chart

Loading chart...

Executive Summary

Miricorilant (CORT-118335) is Corcept Therapeutics' Phase 2 selective glucocorticoid receptor modulator being developed primarily for metabolic dysfunction-associated steatohepatitis (MASH/NASH). On November 3, 2026, Corcept announced positive topline results from the Phase 2b MONARCH trial, showing dose-dependent liver fat reduction and a 19% fibrosis improvement rate on biopsy at 48 weeks with a safety profile similar to placebo. However, an earlier Phase 2 NASH trial using higher doses was terminated for safety concerns. Miricorilant is a secondary pipeline asset behind Corcept's lead drug relacorilant, which has a PDUFA date of December 17, 2026. No Phase 3 program or regulatory filing has been initiated for miricorilant, making it a longer-term, higher-risk opportunity in a notoriously difficult therapeutic area.

How It Works

Miricorilant is an oral small molecule that modulates the glucocorticoid receptor (a protein that mediates the stress hormone cortisol's effects in the body). It acts as a mixed agonist/antagonist of this receptor and also modestly blocks the mineralocorticoid receptor. By fine-tuning cortisol signaling in the liver and other tissues, it aims to reduce fat accumulation and fibrosis (scarring) in the liver, and to counteract the weight gain caused by antipsychotic medications.

Trial Status

The Phase 2b MONARCH trial (NCT06108219) in MASH/NASH completed enrollment of 175 patients and finished on August 24, 2026. Topline results were announced on November 3, 2026, showing dose-dependent reductions in liver fat and a 19% fibrosis improvement rate on biopsy at 48 weeks, with adverse event rates similar to placebo. An earlier Phase 2 NASH trial (NCT03823703) using higher doses (600-900 mg) was terminated due to abnormal lab values. Two Phase 2 trials in antipsychotic-induced weight gain (GRATITUDE I, NCT03818256; GRATITUDE II, NCT04524403) have also been completed/terminated. The company plans to initiate a new Phase 2 study evaluating higher doses of miricorilant.

The Two-Sided Case

▲ Bull Case4
MONARCH Phase 2b results showed dose-dependent reductions in liver fat and a 19% fibrosis improvement rate on biopsy at 48 weeks, with adverse events similar to placebo, suggesting a favorable safety profile at low doses (100-200 mg twice weekly).
The MASH/NASH market is a multi-billion-dollar opportunity with no FDA-approved therapies for NASH with fibrosis, so positive data could position miricorilant as a first-in-class treatment.
Corcept has strong commercial execution (Q3 2026 revenue of $340.5M, up 64% YoY) and a deep pipeline, providing financial resources to advance miricorilant without near-term dilution risk.
The drug's novel mechanism (selective glucocorticoid receptor modulation) is differentiated from other NASH approaches targeting metabolic pathways.
▼ Bear Case5
An earlier Phase 2 NASH trial (NCT03823703) using higher miricorilant doses (600-900 mg) was terminated due to abnormal laboratory values, raising safety questions that will need to be addressed at higher doses.
The MONARCH results are from a Phase 2b study, not a pivotal Phase 3 trial. The path to registration is long and uncertain, with no guarantee that efficacy will replicate in larger, longer studies.
The MASH/NASH field is littered with failed late-stage trials (e.g., Intercept's Ocaliva, Genfit's elafibranor), making it a high-risk therapeutic area.
Miricorilant is a secondary pipeline asset for Corcept behind relacorilant (which has a PDUFA on December 17, 2026) and the approved Korlym/Lifyorli franchise, so it may receive less development focus and resources.
The GRATITUDE trials in antipsychotic-induced weight gain were completed/terminated without announced positive results, and the company has not disclosed plans to advance that indication.

Upcoming Catalysts

  • Initiation of a new Phase 2 study evaluating higher doses of miricorilant in MASH (no specific date announced)
  • Full presentation of MONARCH data at a future medical conference (likely 2027)
  • Any partnership or licensing deal for miricorilant in ex-US markets

Source Filing

The SecBot filing or press-release report that triggered this drug report:

CORCEPT THERAPEUTICS INC 8-K CORT ·Originating report

Sources · 12

Hover a chip for the title
1 en.wikipedia.org2 clinicaltrials.gov3 biospace.com4 morningstar.com5 stockanalysis.com6 clinicaltrialfailures.com7 corcept.com8 trialticker.com9 financialcontent.com10 sec.gov11 stockanalysis.com12 marketscreener.com